Table 1 Clinicopathologic features of breast cancer patients.
Body mass index, kg/m2 (%) | P-value | ||||
|---|---|---|---|---|---|
All patients | <18.5 | 18.5–23.0 | ≥23.0 | ||
Total | 1,225 (100) | 49 (4.0) | 546 (44.6) | 630 (51.4) | |
Age, average (range), years | 51.4 (24–87) | 43.9 (26–67) | 48.5 (24–87) | 54.6 (28–87) | <0.001 |
Histologic grade | 0.157 | ||||
Low | 250 (20.7) | 11 (22.4) | 125 (22.9) | 114 (18.1) | |
Intermediate | 609 (50.4) | 20 (40.8) | 260 (47.6) | 329 (52.2) | |
High | 350 (28.5) | 18 (36.7) | 155 (28.4) | 177 (28.1) | |
Unknown | 16 (1.3) | 0 (0.0) | 6 (1.1) | 10 (1.6) | |
Nuclear grade | 0.263 | ||||
Low | 122 (10.0) | 8 (16.3) | 61 (11.2) | 53 (8.4) | |
Intermediate | 621 (50.7) | 24 (49.0) | 267 (48.9) | 330 (52.4) | |
High | 467 (38.1) | 17 (34.7) | 212 (38.8) | 238 (37.8) | |
Unknown | 15 (1.2) | 0 (0.0) | 6 (1.1) | 9 (1.4) | |
Oestrogen receptor | 0.778 | ||||
Negative | 355 (29.0) | 12 (24.5) | 159 (29.1) | 184 (29.2) | |
Positive | 870 (71.0) | 37 (75.5) | 387 (70.7) | 446 (70.8) | |
Progesterone receptor | 0.726 | ||||
Negative | 473 (38.6) | 18 (36.7) | 205 (37.5) | 250 (39.7) | |
Positive | 752 (61.3) | 31 (63.3) | 341 (62.5) | 380 (60.3) | |
HER2 | 0.921 | ||||
Negative | 873 (71.2) | 34 (69.4) | 391 (71.5) | 448 (71.1) | |
Positive | 306 (25.0) | 12 (24.5) | 133 (24.5) | 161 (25.6) | |
Unknown | 46 (3.8) | 3 (6.1) | 22 (4.0) | 21 (3.3) | |
Ki-67 LI, % | 0.370 | ||||
<14 | 671 (54.8) | 27 (54.0) | 287 (52.5) | 357 (56.7) | |
≥14 | 554 (45.2) | 22 (44.9) | 259 (47.4) | 273 (43.3) | |
Tumour size, mm | 0.001 | ||||
≤20 | 801 (65.4) | 36 (73.5) | 385 (70.5) | 380 (60.3) | |
>20 | 424 (34.6) | 13 (26.5) | 161 (29.5) | 250 (39.7) | |
Positive lymph node, count | 0.216 | ||||
0 | 842 (68.7) | 40 (81.6) | 373 (68.3) | 429 (68.1) | |
1–3 | 296 (24.2) | 6 (12.2) | 139 (25.5) | 151 (24.0) | |
≥4 | 87 (7.1) | 3 (6.1) | 34 (6.2) | 50 (7.9) | |
